ARQT · Arcutis Biotherapeutics, Inc.
$26.97
-0.14 (-0.50%)
At close · Aug 6
Market Cap
$3.39B
Shares
125.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.10
Open$26.07
Day$26.06–27.11
52W$13.70–31.77
Avg vol 30d1.5M
Short int13.6M · 10.8% float · 9.3d
Short vol45%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 31, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+6%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
74%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+2%
trailing
YTD return
−7%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $26 › 200d $25 — 50d above 200d
Institutional flow
Distributing
77 of 268 funds reported for Jun 30 · net -710.2K sh shares · +6 new
Insider flow
Distributing
Net -$13.8K over 90 days · 100% sells
Short interest
Falling
10.84% of float · ▼ -3.3% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
268 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+91%
Y/Y
EPS growth
+89%
Y/Y
Free cash flow
$-6.3M
Balance sheet
$66.1M
net debt
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Net product sales
· 2026 full-year
Initiated
$525M – $540M
prior FY $376.07M
midpoint +41.6% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Golden cross
50d $26 › 200d $25 — 50d above 200d
Institutional flow
Distributing
77 of 268 funds reported for Jun 30 · net -710.2K sh shares · +6 new
Insider flow
Distributing
Net -$13.8K over 90 days · 100% sells
Short interest
Falling
10.84% of float · ▼ -3.3% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
268 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $14
Now $27 · 74%
52-wk high $32
vs 200-day avg +7%
vs 50-day avg +6%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash provided by operating activities | $26.2M | the fourth quarter of 2025 | — |
| ZORYVE net product sales | $372.1M | the full year of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARQT
this stock
Arcutis Biotherapeutics, Inc.
|
$3.39B | -6.7% | +91.3% | — | 10.8% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARQT | -2.7% | -4.9% | +1.9% | +0.9% | -6.7% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -8.3% | -8.2% | -9.3% | -2.2% | -19.6% |
Key facts
CIK
1787306
CUSIP
03969K108
13F (30d)
61 filings
61 filers
Visit website
Investor relations